AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9701195 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 micromol Cu, 0.4 micromol Se, and 100 micromol Zn; group C)
Number of subjects: 20
Study 8010457 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 13
Study 8010457 — intervention group
Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 13
Study 2478849 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwives
Number of subjects: 60
Study 2478849 — intervention group
Group type: COMPARATOR
Intervention: Obstetricians
Number of subjects: 60
Study 1034720 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% mepivacaine
Number of subjects: 230
Study 1034720 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% mepivacaine containing CH3 B12 1,000 μg
Number of subjects: 230
Study 1034720 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of physical saline solution containing CH3 B12 1,000 μg
Number of subjects: 230
Study 1034720 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.5% procaine
Number of subjects: 230
Study 1034720 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.5% procaine containing CH3 B12 1,000 μg
Number of subjects: 230
Study 31821667 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAIL (simulated trail-running exercise)
Number of subjects: 11
Study 31821667 — intervention group
Group type: COMPARATOR
Intervention: REST (no exercise during the day)
Number of subjects: 11
Study 31141632 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus lenalidomide and dexamethasone
Number of subjects: 737
Study 31141632 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone alone (control group)
Number of subjects: 737
Study 28549455 — intervention group
Group type: EXPERIMENTAL
Intervention: e-health driven lifestyle intervention focusing on weight, diet, physical activity, and mental well-being, including 4 coaching sessions between week 6 and month 6 postpartum and 3 coaching sessions during the new pregnancy, with the use of a mobile application connected to a weighing scale and activity tracker.
Number of subjects: 0
Study 28549455 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 24456384 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Lactobacillus casei, Shirota strain (Yakult)
Number of subjects: 87
Study 24456384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 23588944 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg BID
Number of subjects: 204
Study 23588944 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 40 mg QD
Number of subjects: 204
Study 23588944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 21508170 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 134
Study 21508170 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 134
Study 19052126 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (DF) 300 mg once daily for 48 weeks
Number of subjects: 0
Study 19052126 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil 10 mg once daily for 48 weeks
Number of subjects: 0
Study 16824846 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular (LV) pacing
Number of subjects: 74
Study 16824846 — intervention group
Group type: COMPARATOR
Intervention: Biventricular (BiV) pacing
Number of subjects: 74
Study 12612229 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupfeeding
Number of subjects: 700
Study 12612229 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottle-feeding
Number of subjects: 700
Study 12612229 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pacifier introduction (2-5 days)
Number of subjects: 700
Study 12612229 — intervention group
Group type: COMPARATOR
Intervention: Late pacifier introduction (>4 weeks)
Number of subjects: 700
Study 12612229 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupfeeding among cesarean delivered infants
Number of subjects: 700
Study 10914294 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 31
Study 10914294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9322120 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous gastric resection in patients dying from pancreatic carcinoma; prevalence 3.4%.
Number of subjects: 439
Study 9322120 — intervention group
Group type: COMPARATOR
Intervention: Previous gastric resection in patients dying from lung cancer; prevalence 7.6%.
Number of subjects: 439
Study 9322120 — intervention group
Group type: COMPARATOR
Intervention: Age- and sex-matched control group; prevalence 4.4%.
Number of subjects: 439
Study 8400608 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (SCT)
Number of subjects: 44
Study 8400608 — intervention group
Group type: COMPARATOR
Intervention: Control group (500 mg/day calcium intake)
Number of subjects: 44
Study 31493549 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-tDCS
Number of subjects: 12
Study 31493549 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 12
Study 29664663 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation for 12 weeks
Number of subjects: 60
Study 29664663 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study 27055019 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 106
Study 27055019 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination at 14 weeks of age
Number of subjects: 106
Study 27055019 — intervention group
Group type: EXPERIMENTAL
Intervention: HEU infants
Number of subjects: 106
Study 24812434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose treatment group
Number of subjects: 4399
Study 22921287 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirodenafil 100 mg
Number of subjects: 18
Study 22921287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19651694 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational programme
Number of subjects: 82
Study 19651694 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 82
Study 18628517 — intervention group
Group type: EXPERIMENTAL
Intervention: LBW subjects
Number of subjects: 20
Study 18628517 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 20
Study 16858939 — intervention group
Group type: EXPERIMENTAL
Intervention: BVBLUE test
Number of subjects: 173
Study 16858939 — intervention group
Group type: COMPARATOR
Intervention: Gram stain (Nugent score as gold standard)
Number of subjects: 173
Study 11924872 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to a connected mobile phone (900 MHz) for 30 min
Number of subjects: 38
Study 11924872 — intervention group
Group type: COMPARATOR
Intervention: Mobile phone switched off (control group)
Number of subjects: 38
Study 10715366 — intervention group
Group type: EXPERIMENTAL
Intervention: Alesse (20 micrograms ethinyl estradiol)
Number of subjects: 463
Study 10715366 — intervention group
Group type: EXPERIMENTAL
Intervention: Mircette (20 micrograms ethinyl estradiol)
Number of subjects: 463
Study 10715366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho Tri‐Cyclen (35 micrograms ethinyl estradiol)
Number of subjects: 463
Study 10715366 — intervention group
Group type: COMPARATOR
Intervention: 35 micrograms ethinyl estradiol
Number of subjects: 463
Study 7854172 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum use after quitting smoking
Number of subjects: 221
Study 7854172 — intervention group
Group type: EXPERIMENTAL
Intervention: No nicotine exposure after quitting smoking
Number of subjects: 221
Study 7854172 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 221
Study 7854172 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in smoking status
Number of subjects: 221
Study 2015151 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetaphan 0.05 mg kg‐1
Number of subjects: 30
Study 2015151 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetaphan 0.1 mg kg‐1
Number of subjects: 30
Study 2015151 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 30
Study 6461678 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin therapy (13‐cis‐retinoic acid) discontinued for at least 20 weeks
Number of subjects: 20
Study 30834647 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive medication reviews (CMRs) by ward-based pharmacists including follow-up telephone calls after hospital discharge.
Number of subjects: 15
Study 30769063 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded PTFE graft
Number of subjects: 228
Study 30769063 — intervention group
Group type: COMPARATOR
Intervention: Crude PTFE graft
Number of subjects: 228
Study 30769063 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 228
Study 26721873 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii.n.Walk (Wii Fit training, 3x/week for 40 minutes over 4 weeks)
Number of subjects: 28
Study 26721873 — intervention group
Group type: COMPARATOR
Intervention: Cognitive games (Control group)
Number of subjects: 28
Study 26018207 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 25
Study 26018207 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 25
Study 22538473 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulated autogenous bone (PAB)
Number of subjects: 30
Study 22538473 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixtures of PAB and beta‐tricalciumphosphate (PAB/β‐TCP)
Number of subjects: 30
Study 22538473 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixtures of PAB and β‐TCP and hydroxyapatite (PAB/HA/β‐TCP)
Number of subjects: 30
Study 22538473 — intervention group
Group type: COMPARATOR
Intervention: Control group (PAB alone)
Number of subjects: 30
Study 21389859 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency medicine rotation (theoretical and practical course)
Number of subjects: 98
Study 21389859 — intervention group
Group type: COMPARATOR
Intervention: Pretest scores
Number of subjects: 98
Study 19321990 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF(2) (approx. 0.1 M F)
Number of subjects: 67
Study 19321990 — intervention group
Group type: EXPERIMENTAL
Intervention: HF (0.027, 0.055, 0.082 M F)
Number of subjects: 67
Study 19321990 — intervention group
Group type: EXPERIMENTAL
Intervention: TiF(4)
Number of subjects: 67
Study 19321990 — intervention group
Group type: COMPARATOR
Intervention: NaF (0.1 M F)
Number of subjects: 67
Study 17367306 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment education programme
Number of subjects: 32
Study 17367306 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment education programme with parental involvement
Number of subjects: 32
Study 17367306 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list design)
Number of subjects: 32
Study 15362205 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP9 expression
Number of subjects: 41
Study 11848262 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg perindopril and 0.625 mg indapamide
Number of subjects: 235
Study 11848262 — intervention group
Group type: COMPARATOR
Intervention: 2 mg perindopril
Number of subjects: 235
Study 11848262 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg indapamide
Number of subjects: 235
Study 11848262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 11848262 — intervention group
Group type: COMPARATOR
Intervention: Combination vs Losartan
Number of subjects: 235
Study 10437260 — intervention group
Group type: EXPERIMENTAL
Intervention: Filiform needle group
Number of subjects: 48
Study 10437260 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-injection group
Number of subjects: 48
Study 10437260 — intervention group
Group type: COMPARATOR
Intervention: Western medicine group
Number of subjects: 48
Study 7873261 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mgs/12 h i.v.)
Number of subjects: 282
Study 7873261 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (1,200 mgs/i.v./day)
Number of subjects: 282
Study 3279578 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 55
Study 3279578 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine + low-dose steroids
Number of subjects: 55
Study 3279578 — intervention group
Group type: COMPARATOR
Intervention: High-dose steroids
Number of subjects: 55
Study 3279578 — intervention group
Group type: COMPARATOR
Intervention: Low-dose steroids
Number of subjects: 55
Study 30755451 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship (AMS) intervention
Number of subjects: 79
Study 30755451 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 79
Study 30755451 — intervention group
Group type: EXPERIMENTAL
Intervention: AMS intervention
Number of subjects: 79
Study 29221470 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 60
Study 29221470 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 60
Study 26011593 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (BAT)
Number of subjects: 146
Study 26011593 — intervention group
Group type: COMPARATOR
Intervention: Control (ongoing guideline-directed medical and device therapy)
Number of subjects: 146
Study 24800384 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre intake
Number of subjects: 90
Study 24800384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake
Number of subjects: 90
Study 24800384 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity levels
Number of subjects: 90
Study 21616115 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 200000
Study 21616115 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BCG revaccination)
Number of subjects: 200000
Study 19671875 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (cyclophosphamide, i.v. methotrexate, and 5-fluorouracil or cyclophosphamide, i.v. doxorubicin, and 5-fluorouracil +/- tamoxifen)
Number of subjects: 0
Study 19671875 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 0
Study 17116185 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg lipo‐PGE(1) given as a continuous infusion over 5 days, along with 48 mg methylprednisolone for 5 days
Number of subjects: 270
Study 17116185 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) along with 48 mg methylprednisolone for 5 days
Number of subjects: 270
Study 15209960 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 26
Study 15209960 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen
Number of subjects: 26
Study 11727357 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + TMG (2 mg estradiol and 0.5 mg trimegestone)
Number of subjects: 634
Study 11727357 — intervention group
Group type: COMPARATOR
Intervention: E2V + NG (estradiol valerate and norgestrel)
Number of subjects: 634
Study 11727357 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + TMG
Number of subjects: 634
Study 11727357 — intervention group
Group type: COMPARATOR
Intervention: E2V + NG
Number of subjects: 634
Study 9135704 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg oxandrolone daily
Number of subjects: 16
Study 9135704 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg testosterone monthly intramuscular injections
Number of subjects: 16
Study 9135704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7963510 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (350 mmol/day)
Number of subjects: 12
Study 7963510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake (10 mmol/day)
Number of subjects: 12
Study 7963510 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium intake (control)
Number of subjects: 12
Study 3070420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Nimodipine
Number of subjects: 188
Study 3070420 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 188
Study 30601058 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial decompression
Number of subjects: 0
Study 30601058 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopy only (placebo surgery)
Number of subjects: 0
Study 30601058 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 28546319 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS‐MA
Number of subjects: 326
Study 28546319 — intervention group
Group type: COMPARATOR
Intervention: SAU
Number of subjects: 326
Study 26906448 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-and-About program (behavior change program with training workshop, barrier identification, booster session, printed educational materials, audit, and feedback)
Number of subjects: 22
Study 26906448 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-and-About program (behavior change program)
Number of subjects: 22
Study 26906448 — intervention group
Group type: COMPARATOR
Intervention: Control group (printed clinical guidelines only)
Number of subjects: 22
Study 25011691 — intervention group
Group type: EXPERIMENTAL
Intervention: Manic patients
Number of subjects: 110
Study 25011691 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 110
Study 25011691 — intervention group
Group type: COMPARATOR
Intervention: Euthymic patients
Number of subjects: 110
Study 25011691 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed patients
Number of subjects: 110
Study 25011691 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of illness
Number of subjects: 110
Study 23075000 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention with individualized email-based feedback for 10 weeks
Number of subjects: 0
Study 23075000 — intervention group
Group type: COMPARATOR
Intervention: General supportive/motivational messages (for both INT and CTL)
Number of subjects: 0
Study 18753471 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg of morphine plus saline solution (MO)
Number of subjects: 41
Study 18753471 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg of morphine plus a 5-mg ketamine bolus (MK)
Number of subjects: 41
Study 17242418 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatments (psychosocial and pharmacological)
Number of subjects: 8
Study 14684584 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3 6 g once daily for one year
Number of subjects: 36
Study 14684584 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for one year
Number of subjects: 36
Study 14684584 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 36
Study 14684584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12116511 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening strips containing hydrogen peroxide
Number of subjects: 132
Study 12116511 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuance of the whitening agent
Number of subjects: 132
Study 10836083 — intervention group
Group type: EXPERIMENTAL
Intervention: Carlens tube
Number of subjects: 62
Study 10836083 — intervention group
Group type: COMPARATOR
Intervention: Robertshaw tube
Number of subjects: 62
Study 10836083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 10836083 — intervention group
Group type: EXPERIMENTAL
Intervention: Robertshaw tube with fiberoptic bronchoscope
Number of subjects: 62
Study 8583095 — intervention group
Group type: EXPERIMENTAL
Intervention: Heater probe thermocoagulation (HPT)
Number of subjects: 80
Study 8583095 — intervention group
Group type: COMPARATOR
Intervention: Multipolar electrocoagulation (MPEC)
Number of subjects: 80
Study 2252171 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with methohexital and fentanyl
Number of subjects: 18
Study 2252171 — intervention group
Group type: COMPARATOR
Intervention: Combined anaesthesia with alfentanil and N2O
Number of subjects: 18
Study 31259 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 27
Study 31259 — intervention group
Group type: COMPARATOR
Intervention: Nonselective beta-blockers
Number of subjects: 27
Study 31268223 — intervention group
Group type: EXPERIMENTAL
Intervention: GroupCoreDIST
Number of subjects: 80
Study 31282768 — intervention group
Group type: EXPERIMENTAL
Intervention: TX‐001HR (1/100 mg, 0.5/100 mg, 0.5/50 mg, 0.25/50 mg)
Number of subjects: 0
Study 31282768 — intervention group
Group type: EXPERIMENTAL
Intervention: TX‐001HR
Number of subjects: 0
Study 31282768 — intervention group
Group type: EXPERIMENTAL
Intervention: TX‐001HR (1 mg/100 mg)
Number of subjects: 0
Study 27680426 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 20
Study 27680426 — intervention group
Group type: COMPARATOR
Intervention: Ankle-Foot Orthosis (AFO)
Number of subjects: 20
Study 26080370 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3)
Number of subjects: 198
Study 23627534 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched Environment (EE)
Number of subjects: 29
Study 23627534 — intervention group
Group type: COMPARATOR
Intervention: Non-enriched environment (Control)
Number of subjects: 29
Study 22324056 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensation group treatment programme
Number of subjects: 72
Study 22324056 — intervention group
Group type: EXPERIMENTAL
Intervention: Restitution group treatment programme
Number of subjects: 72
Study 22324056 — intervention group
Group type: COMPARATOR
Intervention: Self-help group control
Number of subjects: 72
Study 19438472 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (Lenograstim, 263 microg/d)
Number of subjects: 803
Study 19438472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study 17263856 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol-containing chewing gum (total dose=6.18 g/day)
Number of subjects: 128
Study 17263856 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol and maltitol-containing pellets
Number of subjects: 128